Molecular targets in medullary thyroid carcinoma

Gene Therapy and Molecular Biology

Volumn 12, Issue 2, 2008, Pages 181-188

  Moore, Sam W ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Medullary thyroid carcinoma; Molecular targets; Prophylactic thyroidectomy; RET activation; RET structure

Indexed keywords

EID: 75749117295     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30, 216-222.
2. Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG, Pierotti MA (1998) Grb2 binding to the different isoforms of Ret tyrosine kinase. Oncogene 17, 1079-1087.
3. Andl CD, Rustgi AK (2005) No One-way Street, Cross-Talk between E-cadherin and Receptor Tyrosine kinase RTK Signaling, A Mechanism to Regulate RTK Activity. Cancer Biol Ther
4. Arighi E, Alberti L, Torriti F, Ghizzoni S, Rizzetti MG, Pelicci G, Pasini B, Bongarzone I, Piutti C, Pierotti MA, Borrello MG (1997) Identification of Shc docking site on Ret tyrosine kinase. Oncogene 14, 773-782.
5. Arighi E, Popsueva A, Degl'innocenti D, Borrello MG, Carniti C, Perala NM, Pierotti MA, Sariola H (2004) Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease. Mol Endocrinol 18, 1004-1017.
6. Asai N, Iwashita T, Matsuyama M, Takahashi M (1995) Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15, 1613-1619.
7. Ball DW (2007) Medullary thyroid cancer, therapeutic targets and molecular markers. Curr Opin Oncol 19, 18-23.
8. Baloh RH, Tansey MG, Golden JP, Creedon DJ, Heuckeroth RO, Keck CL, Zimonjic DB, Popescu NC, Johnson EM, Jr, Milbrandt J (1997) TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. Neuron 18, 793-802.
9. Blank RD, Sklar CA, Dimich AB, LaQuaglia MP, Brennan MF (1996) Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds. Cancer 78, 1996-2003.
10. Bordeaux MC, Forcet C, Granger L, Corset V, Bidaud C, Billaud M, Bredesen DE, Edery P, Mehlen P (2000) The RET protooncogene induces apoptosis, a novel mechanism for Hirschsprung disease. EMBO J 19, 4056-4063.
11. Borrego S, Eng C, Sanchez B, Saez ME, Navarro E, Antinolo G (1998) Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J Clin Endocrinol Metab 83, 3361-3364.
12. Borst MJ, VanCamp JM, Peacock ML, Decker RA (1995) Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery 117, 386-391.
13. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98, 326-334.
14. Carlomagno F, De Vita G, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, Kraus MH, Di Fiore PP, Fusco A, Santoro M (1996) Molecular heterogeneity of RET loss of function in Hirschsprung's disease. EMBO J 15, 2717-2725.
15. Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M (1997) The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 57, 391-395.
16. Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix A, Wells SA Jr, Goodfellow PJ (1994) Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 55, 1076-1082.
17. Caron P, Attie T, David D, Amiel J, Brousset F, Roger P, Munnich A, Lyonnet S (1996) C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Clin Endocrinol Metab 81, 2731-2733.
18. Ceccherini I, Bocciardi R, Luo Y, Pasini B, Hofstra R, Takahashi M, Romeo G (1993) Exon structure and flanking intronic sequences of the human RET proto-oncogene. Biochem Biophys Res Commun 196, 1288-1295.
19. Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T, Lenoir GM, Santoro M, Billaud M (1998) Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. Oncogene 17, 2851-2861.
20. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer, Results From a Phase II Study. J Clin Oncol in press.
21. Colombo-Benkmann M, Li Z, Riemann B, Hengst K, Herbst H, Keuser R, Gross U, Rondot S, Raue F, Senninger N, Pützer BM, Frank-Raue K (2008) Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. Eur J Endocrinol 158, 811-6
22. Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA (2008) RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor EGFR activation, evidence for molecular and functional interactions between RET and EGFR. Cancer Res 68, 4183-4191.
23. Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F (2004) Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96, 1006-1014.
24. de Groot JW, Links TP, Rouwe CW, van der Wal JE, Hofstra RM, Plukker JT (2006) Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation, description of 20 cases and recommendations based on the literature. Ned Tijdschr Geneeskd 150, 311-318.
25. Decker RA, Peacock ML (1998) Occurrence of MEN 2a in familial Hirschsprung's disease, a new indication for genetic testing of the RET proto-oncogene. J Pediatr Surg 33, 207-214.
26. Decker RA, Peacock ML, Watson P (1998) Hirschsprung disease in MEN 2A, increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet 7, 129-134.
27. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2, 851-856.
28. Drosten M Putzer BM (2003) Gene therapeutic approaches for medullary thyroid carcinoma treatment. J Mol Med 81, 411-419.
29. Dvorakova S, Dvorakova K, Malikova M, Skaba R, Vlcek P, Bendlova B (2005) A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung's disease. J Pediatr Surg 40, e1-6.
30. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D, Kodet R, Krskova L, Vlcek P, Astl J, Vesely D, Bendlova B (2008) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 284, 21-27.
31. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S, Nihoul-Fékété C, Ponder BA, Munnich A (1994) Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367, 378-380.
32. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives, experience with 807 individuals at one center 3. J Clin Endocrinol Metab 92, 4725-4729.
33. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA (1995) A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10, 509.-513.
34. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, Rondot S, Hoppner W, Raue F (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy, impact of individual RET genotype. Eur J Endocrinol 155, 229-236.
35. Frank-Raue K, Rondot S, Schulze E, Raue F (2007) Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin Lab 53, 273-282.
36. Geneste O, Bidaud C, De Vita G, Hofstra RM, Tartare-Deckert S, Buys CH, Lenoir GM, Santoro M, Billaud M (1999) Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site. Hum Mol Genet 8, 1989-1999.
37. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della PG, Fusco A, Vecchio G (1990) PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60, 557-563
38. Griseri P, Bachetti T, Puppo F, Lantieri F, Ravazzolo R, Devoto M, Ceccherini I (2005) A common haplotype at the 5' end of the RET proto-oncogene, overrepresented in Hirschsprung patients, is associated with reduced gene expression. Hum Mutat 25, 189-195.
39. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS (2008) Phase II Trial of Sorafenib in Advanced Thyroid Cancer. J Clin Oncol in press.
40. Inoue K, Shimotake T, Inoue K, Tokiwa K (1999) Mutational analysis of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Pediatr Surg 34, 1552-1554.
41. Iwashita T, Murakami H, Asai N, Takahashi M (1996) Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. Hum Mol Genet 5, 1577-1580.
42. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la CA (2008) Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 105, 7269-7274.
43. Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock BW, Fox GM (1996) GDNF-induced activation of the RET protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85, 1113-1124.
44. Johanson V, Ahlman H, Bernhardt P, Jansson S, Kolby L, Persson F, Stenman G, Sward C, Wangberg B, Stridsberg M, Nilsson O (2007) A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Endocr Relat Cancer 14, 433-444.
45. keno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA (2007) The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 67, 6956-6964.
46. Kjaer S Ibanez CF (2003) Identification of a surface for binding to the GDNF-GFR alpha 1 complex in the first cadherin-like domain of RET. J Biol Chem 278, 47898-47904.
47. Klugbauer S, Rabes HM (1999) The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene 18, 4388-4393.
48. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibanez CF, McDonald NQ (2006) Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281, 33577-33587.
49. Lorenzo MJ, Gish GD, Houghton C, Stonehouse TJ, Pawson T, Ponder BA, Smith DP (1997) RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2. Oncogene 14, 763-771.
50. Lundgren TK, Scott RP, Smith M, Pawson T, Ernfors P (2006) Engineering the recruitment of phosphotyrosine binding domain-containing adaptor proteins reveals distinct roles for RET receptor-mediated cell survival. J Biol Chem 281, 29886-29896.
51. Luo Y, Ceccherini I, Pasini B, Matera I, Bicocchi MP, Barone V, Bocciardi R, Kääriäinen H, Weber D, Devoto M, Romeo G (1993) Close linkage with the RET proto-oncogene and boundaries of deletion mutations in autosomal dominant Hirschsprung disease. Hum Mol Genet 2, 1803-1808.
52. Machens A Dralle H (2007a) Very early manifestation of hereditary medullary thyroid cancer in carriers of intracellulsar-domain RET mutations. J Pediatr Surg 42, 1153.
53. Machens A, Dralle H (2008) Familial prevalence and age of RET germline mutations, implications for screening. Clin Endocrinol 69, 81-7.
54. Machens A, Dralle H, (2007b) Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 31, 957-68.
55. Moore SW, Appfelstaedt J, Zaahl MG (2007) Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. J Pediatr Surg 42, 326-332.
56. Moore SW, Zaahl MG (2008) Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET. Pediatr Surg Int 24, 521-530.
57. Moretti F, Nanni S, Pontecorvi A (2000) Molecular pathogenesis of thyroid nodules and cancer. Baillieres Best Pract Res Clin Endocrinol Metab 14, 517-539.
58. Mulligan LM, Eng C, Attié T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, Venter DJ, Munnich A, Ponder BAJ (1994) Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 3, 2163-2167.
59. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458-460.
60. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA (1997) Distinct pattern of ret oncogene rearrangements in morphological variants of radiationinduced and sporadic thyroid papillary carcinomas in children. Cancer Res 57, 1690-1694.
61. Pachnis V, Mankoo B, Constantini F (1993) Expression of c-ret protooncogene during mouse embryogenesis. Development 119, 1005-1017.
62. Pasini B, Rossi R, Ambrosio MR, Zatelli MC, Gullo M, Gobbo M, Collini P, Pansini G, Trasforini G, degli Uberti EC (2002) RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Surgery 131, 373-381.
63. Pelet A, Geneste O, Edery P, Pasini A, Chappuis S, Atti T, Munnich A, Lenoir G, Lyonnet S, Billaud M (1998) Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. J Clin Invest 101, 1415-1423.
64. Pelicci G, Troglio F, Bodini A, Melillo RM, Pettirossi V, Coda L, De Giuseppe A, Santoro M, Pelicci PG (2002) The neuron-specific Rai ShcC adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 22, 7351-7363.
65. Peretz H, Luboshitsky R, Baron E, Biton A, Gershoni R, Usher S, Grynberg E, Yakobson E, Lapidot M (1997) Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting. Hum Mutat 10, 155-159.
66. Petrangolini G, Cuccuru G, Lanzi C, Tortoreto M, Belluco S, Pratesi G, Cassinelli G, Zunino F (2006) Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol 72, 405-414.
67. Pinna G, Orgiana G, Riola A, Ghiani M, Lai ML, Carcassi C, Mariotti S (2007) RET Proto-Oncogene in Sardinia, V804M Is the Most Frequent Mutation and May Be Associated with FMTC/MEN-2A Phenotype. Thyroid 17, 101-104.
68. Porter AC Vaillancourt RR (1998) Tyrosine kinase receptoractivated signal transduction pathways which lead to oncogenesis. Oncogene 17, 1343-1352.
69. Rabes HM, Klugbauer S (1998) Molecular genetics of childhood papillary thyroid carcinomas after irradiation, high prevalence of RET rearrangement. Recent Results Cancer Res 154, 248-264.
70. Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, Seri M, Yin L, Lerone M, Jasonni V, Martucciello G (1998) Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med 243, 515-520.
71. Saarma M (2001) GDNF recruits the signaling crew into lipid rafts. Trends Neurosci 24, 427-429.
72. Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M (2001) Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res 61, 1426-1431.
73. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP (1995a) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267, 381-383.
74. Santoro M, Grieco M, Melillo RM, Fusco A, Vecchio G (1995b) Molecular defects in thyroid carcinomas, role of the RET oncogene in thyroid neoplastic transformation. Eur J Endocrinol 133, 513-522.
75. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G (2002) Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 963, 116-121.
76. Sijmons RH, Hofstra RM, Wijburg FA, Links TP, Zwierstra RP, Vermey A, Aronson DC, Tan-Sindhunata G, Brouwers-Smalbraak GJ, Maas SM, Buys CH (1998) Oncological implications of RET gene mutations in Hirschsprung's disease. Gut 43, 542-547.
77. Skinner MA (2003) Management of hereditary thyroid cancer in children. Surg Oncol 12, 101-104.
78. Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M (1999) Co-segregation of MEN2 and Hirschsprung's disease, the same mutation of RET with both gain and loss-of-function? Hum Mutat 13, 331-6
79. Takahashi M, Ritz J, Cooper GM (1985) Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42, 581-588.
80. Tufro A, Teichman J, Banu N, Villegas G (2007) Crosstalk between VEGF-A/VEGFR2 and GDNF/RET signaling pathways. Biochem Biophys Res Commun 358, 410-416.
81. van Heyningen V (1994) Genetics.One gene--four syndromes. Nature 367, 319-320.
82. Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu P (1982) Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1, 603-607.
83. Wang XJ, Chen XH, Yang XY, Geng MY, Wang LM (2007) Acidic oligosaccharide sugar chain, a marine-derived oligosaccharide, activates human glial cell line-derived neurotrophic factor signalling. Neurosci Lett 417, 176-180.
84. Wong A, Bogni S, Kotka P, de Graaff E, D'Agati V, Costantini F, Pachnis V (2005) Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform. Mol Cell Biol 25, 9661-9673.
85. Yu XM, Lo CY, Lam AK, Leung P, Luk JM (2008) Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 247, 483-489.